## Teresa Antonia Santantonio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4475034/publications.pdf

Version: 2024-02-01

32 papers 1,515 citations

623188 14 h-index 454577 30 g-index

34 all docs

34 docs citations

times ranked

34

2270 citing authors

#	Article	IF	Citations
1	Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders. Infectious Diseases, 2022, 54, 241-246.	1.4	8
2	Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees. Frontiers in Immunology, 2022, 13, 820250.	2.2	20
3	Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS oVâ€2. Journal of Medical Virology, 2021, 93, 1739-1742.	2.5	32
4	General Practitioners as partners for a shared management of chronic HIV infection: An insight into the perspectives of Italian People Living with HIV. PLoS ONE, 2021, 16, e0254404.	1.1	1
5	Guillain-Barr $\tilde{A}$ $\otimes$ syndrome as only manifestation of COVID-19 infection. Clinical Neurology and Neurosurgery, 2021, 207, 106775.	0.6	5
6	Safety and heart rate changes in Covid-19 patients treated with Remdesivir. International Journal of Infectious Diseases, 2021, $112$ , $254$ - $257$ .	1.5	18
7	Severity of COVID-19 Patients Predicted by Serum Sphingolipids Signature. International Journal of Molecular Sciences, 2021, 22, 10198.	1.8	45
8	Low Prevalence of Antibodies to SARS-CoV-2 and Undetectable Viral Load in Seropositive Blood Donors from South-Eastern Italy. Acta Haematologica, 2021, 144, 580-584.	0.7	9
9	Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2?. Journal of Clinical Medicine, 2021, 10, 309.	1.0	28
10	Sex and gender differences in COVID-19: an Italian local register-based study. BMJ Open, 2021, 11, e051506.	0.8	29
11	Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic. Antibiotics, 2021, 10, 1477.	1.5	5
12	Resistance Associated Mutations in HCV Patients Failing DAA Treatment. New Microbiologica, 2021, 44, 12-18.	0.1	9
13	Severe systemic thrombosis in a young COVID-19 patient with a rare homozygous prothrombin G20210A mutation. Infezioni in Medicina, 2021, 29, 259-262.	0.7	1
14	SARS-COV-2 Serological Profile in Healthcare Professionals of a Southern Italy Hospital. International Journal of Environmental Research and Public Health, 2020, 17, 9324.	1.2	12
15	Baricitinib: A chance to treat COVIDâ€19?. Journal of Medical Virology, 2020, 92, 2343-2344.	2.5	16
16	Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The "STORE―Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 290-294.	0.9	3
17	Health concerns for HIV-exposed but non-infected children. Minerva Ginecologica, 2020, 72, 120-121.	0.8	O
18	The absence of culturable bacteria from at term placentae from HIV-negative and positive women argues against a placental unique microbiota. Minerva Ginecologica, 2020, 71, 476-477.	0.8	2

#	Article	IF	CITATIONS
19	Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. Scientific Reports, 2019, 9, 585.	1.6	6
20	Treatment of acute hepatitis C: recommendations from an expert panel of the Italian Society of Infectious and Tropical Diseases. Infection, 2018, 46, 183-188.	2.3	7
21	Long-term efficacy and safety of switching from lamivudine + adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. Digestive and Liver Disease, 2017, 49, 530-534.	0.4	6
22	Correlation between knowledge on transmission and prevention of HIV/STI and proficiency in condom use among male migrants from Africa and Middle East evaluated by a Condom Use Skills score using a wooden penile model. BMC Research Notes, 2017, 10, 216.	0.6	13
23	Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population. PLoS ONE, 2017, 12, e0172101.	1.1	24
24	Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection. PLoS Pathogens, 2016, 12, e1005894.	2.1	31
25	Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. Journal of Antimicrobial Chemotherapy, 2015, 70, 1150-1154.	1.3	42
26	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut, 2015, 64, 1289-1295.	6.1	178
27	Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. Hepatology, 2014, 59, 2101-2109.	3.6	38
28	Reply. Hepatology, 2014, 60, 2129-2129.	3.6	0
29	Chronic hepatitis B: Advances in treatment. World Journal of Hepatology, 2014, 6, 284.	0.8	30
30	Acute hepatitis C: Current status and remaining challenges. Journal of Hepatology, 2008, 49, 625-633.	1.8	129
31	Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology, 2007, 45, 579-587.	3.6	585
32	Efficacy of a 24-week course of PEG-interferon $\hat{l}_{\pm}$ -2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. Journal of Hepatology, 2005, 42, 329-333.	1.8	151